Pulmatrix inc PULM.US 總覽分析

美股醫療保健
(PULM 無簡報檔)

PULM 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上

PULM 近期報酬表現

0.65%

Pulmatrix inc

4.57%

同產業平均

3.26%

S&P500

與 PULM 同產業的標的表現

  • ALGS Aligos therapeutics inc
    價值 3 分趨勢 1 分波段 2 分籌碼 1 分股利 1 分
    查看更多

PULM 公司資訊

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company's proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company's therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

PULM 股價